Global Muscle Wasting Disorders Market Report By Туре (Muscular Dystrophy (Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Myotonic Muscular Dystrophy, Congenital Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)), Muscular Atrophy (Physiologic Atrophy, Pathologic Atrophy, Neurogenic Atrophy)), By Treatment Type (Medications, Physical Therapy (Ultrasound Therapy, Electric Simulation), Nutritional Therapy, Surgery, Gene Therapy, Others (Occupational Therapy, Respiratory Therapy, Assistive Devices. Etc.)), By End-user (Hospitals, Rehab Centers, Specialty Clinics, Others (Homecare, Etc.)) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2022-2030

The global demand for Muscle Wasting Disorders Market is presumed to reach the market size of nearly USD 47.47 BN by 2030 from USD 14.29 BN in 2022 with a CAGR of 16.19% under the study period 2023 - 2030.

Muscle wasting disorders, often termed muscle atrophy, encompasses a collection of medical conditions defined by the decline in both muscle mass and strength. This phenomenon arises when the typical equilibrium between muscle protein synthesis and muscle protein is disturbed, resulting in an overall reduction in muscle tissue. Muscle wasting can affect various muscle groups in the body and can be caused by a range of factors, including certain neurological conditions, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, and peripheral neuropathy, which can lead to muscle wasting due to the disruption of nerve signals that control muscle movement.

Market Dynamics

Various factors influence the diagnosis, treatment, and management of muscle wasting disorders. Advancements in research and clinical understanding, along with healthcare funding and policies, contribute to improved patient care. An aging global population has led to an increased prevalence of age-related muscle wasting conditions like sarcopenia, raising awareness and the need for appropriate healthcare resources. Patient advocacy groups and awareness campaigns work to promote research and support affected individuals. Technological advances in medical tools aid in early detection, while ongoing pharmaceutical research may lead to treatments for muscle wasting in certain disorders. The importance of proper nutrition and protein intake, as well as the role of rehabilitation and physical therapy in preserving muscle function and mobility, are increasingly recognized. The primary focus in addressing muscle wasting disorders is to enhance the quality of life, functional capabilities, and overall well-being of affected individuals within the healthcare framework.

The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of muscle wasting disorders. The growth and trends of muscle wasting disorders industry provide a holistic approach to this study. 

Market Segmentation

This section of the muscle wasting disorders market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Туре

• Muscular Dystrophy (Duchenne Muscular Dystrophy (Dmd), Becker Muscular Dystrophy (Bmd), Myotonic Muscular Dystrophy, Congenital Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Etc.))
• Muscular Atrophy (Physiologic Atrophy, Pathologic Atrophy, Neurogenic Atrophy)

By Treatment Type

• Medications
• Physical Therapy (Ultrasound Therapy, Electric Simulation)
• Nutritional Therapy
• Surgery
• Gene Therapy
• Others (Occupational Therapy, Respiratory Therapy, Assistive Devices. Etc.)

By End-User

• Hospitals
• Rehab Centers
• Specialty Clinics
• Others (Homecare, Etc.)

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Muscle Wasting Disorders market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

Global Muscle Wasting Disorders Market Share by Region (Representative Graph)

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Muscle Wasting Disorders market include Biogen, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.), PTC Therapeutics, Inc., Teva Pharmaceutical Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.